Cited 0 times in
The Effect of Ramosetron on Remifentanil in Preventing Emergence Cough from Sevoflurane Anesthesia in Female Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이혜선 | - |
dc.date.accessioned | 2022-12-22T02:21:37Z | - |
dc.date.available | 2022-12-22T02:21:37Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 1381-6128 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191543 | - |
dc.description.abstract | Background: Remifentanil reduces cough during extubation. Ramosetron, a 5-HT3 receptor antagonist, is a potent antiemetic. Regarding the antitussive property of 5-HT receptor agonists, ramosetron can mediate the cough reflex by increasing the remifentanil requirement. This study evaluated the effect of ramosetron on the optimal effect-site concentration (Ce) of remifentanil for preventing emergence cough from sevoflurane anesthesia in female patients. Methods: Forty-seven randomly selected female patients undergoing laparoscopic cholecystectomy received either ramosetron 0.3 mg (n = 23) or the same volume of normal saline (n = 24) intravenously at the end of surgery. The remifentanil Ce using target-controlled infusion in 50% of patients (EC50) and 95% of patients (EC95) were assessed using Dixon's up-and-down or isotonic regression method with a bootstrapping approach. Results: Using Dixon's up-and-down method, the EC50 of remifentanil in the control group (1.33 ± 0.38 ng/mL) was comparable to that of ramosetron group (1.50 ± 0.69 ng/mL) (P = 0.615). Using isotonic regression analysis, the EC50 (83% confidence interval) did not differ between the two groups (1.17 [0.86-1.43] ng/mL and 1.13 [0.68-1.56] ng/mL in control and ramosetron groups). However, the EC95 (95% confidence interval) was significantly lower in the control group than in the ramosetron group (1.90 [1.45-1.96] ng/mL and 2.92 [2.35-2.97] ng/mL). Conclusion: Remifentanil Ce for preventing emergence cough was higher in the ramosetron group than in the control group. It may indicate the lowering effect of ramosetron on the antitussive activity of remifentanil. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Bentham Science Publishers | - |
dc.relation.isPartOf | CURRENT PHARMACEUTICAL DESIGN | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Anesthesia* | - |
dc.subject.MESH | Antitussive Agents* / therapeutic use | - |
dc.subject.MESH | Benzimidazoles | - |
dc.subject.MESH | Cough / drug therapy | - |
dc.subject.MESH | Cough / prevention & control | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Piperidines / therapeutic use | - |
dc.subject.MESH | Remifentanil / therapeutic use | - |
dc.subject.MESH | Sevoflurane / therapeutic use | - |
dc.title | The Effect of Ramosetron on Remifentanil in Preventing Emergence Cough from Sevoflurane Anesthesia in Female Patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Yonsei Biomedical Research Center (연세의생명연구원) | - |
dc.contributor.googleauthor | Ji Ho Kim | - |
dc.contributor.googleauthor | Ga Yun Lee | - |
dc.contributor.googleauthor | Hye Sun Lee | - |
dc.contributor.googleauthor | Sung Yong Park | - |
dc.identifier.doi | 10.2174/1381612828666220412101447 | - |
dc.contributor.localId | A03312 | - |
dc.relation.journalcode | J00681 | - |
dc.identifier.eissn | 1873-4286 | - |
dc.identifier.pmid | 35418281 | - |
dc.identifier.url | https://www.eurekaselect.com/article/122485 | - |
dc.subject.keyword | Anesthesia | - |
dc.subject.keyword | emergence cough | - |
dc.subject.keyword | extubation | - |
dc.subject.keyword | female | - |
dc.subject.keyword | ramosetron | - |
dc.subject.keyword | remifentanil | - |
dc.contributor.alternativeName | Lee, Hye Sun | - |
dc.contributor.affiliatedAuthor | 이혜선 | - |
dc.citation.volume | 28 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 1359 | - |
dc.citation.endPage | 1366 | - |
dc.identifier.bibliographicCitation | CURRENT PHARMACEUTICAL DESIGN, Vol.28(16) : 1359-1366, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.